Abstract
Thirty-three patients with ALL/AUL in first relapse were treated with an induction of prednisone, vindesine, daunorubicin, Erwinia asparaginase, i.t. MTX (phase I), high-dose cytarabine, and etoposide (phase II). Twenty-one (64%) achieved a complete remission, one a partial remission. Side effects of induction-phase I were predominantly hematological with subsequent infections and gastrointestinal toxicity. In phase II some patients had additional cutaneous, ocular, and hepatic toxicity. The treatment efficiently induced remissions with tolerable toxicity in relapsed ALL. The disease-free survival, however, needs to be improved.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Bone Marrow Transplantation
-
Brain Neoplasms / drug therapy
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Dexamethasone / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Germany, West / epidemiology
-
Humans
-
Ifosfamide / administration & dosage
-
Leucovorin / administration & dosage
-
Life Tables
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Multicenter Studies as Topic
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / surgery
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
-
Prednisone / administration & dosage
-
Spinal Cord Neoplasms / drug therapy
-
Teniposide / administration & dosage
-
Testicular Neoplasms / drug therapy
-
Vindesine / administration & dosage
Substances
-
Cytarabine
-
Etoposide
-
Dexamethasone
-
Teniposide
-
Asparaginase
-
Leucovorin
-
Vindesine
-
Ifosfamide
-
Prednisone
-
Methotrexate
-
Daunorubicin